Skip to content

Drug safety

ISSN 1179-1942

3 papers in the library · 1 citation · publishing 1996-2026

Papers

Sort Most recent Most cited

Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study.

Drug safety September 2, 2026 You Wang, Alexandra S Storaci, G Caleb Alexander et al.

Treatment-resistant depression (TRD) is associated with elevated suicide risk, but real-world evidence on whether esketamine reduces suicide attempts and intentional self-harm remains limited. The aim was to estimate whether current esketamine exposure was associated with a higher or lower risk of recorded nonfatal, medically attended suicide attempt or intentional self-harm among adults with...

Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.

Drug safety May 1, 2025 Ahmed Al-Imam, Riccardo Lora, Marek A Motyka et al. 1 citation

Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuable user insights, but analyses of these experiences using natural language processing (NLP) remain scarce. This study aims to utilize NLP, including sentiment and lexicon analysis, to examine user-generated experience reports on psilocybin-containing...

DOI: 10.1007/s40264-025-01530-z (opens in new tab) Full text (opens in new tab) Consciousness research Altered states Psychedelics Drug effects

Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Drug safety August 1996 U D McCann, S O Slate, George A. Ricaurte

3,4-Methylenedioxymethamphetamine (MDMA; 'ecstasy') is an increasingly popular recreational drug in the US, Western Europe and Australia. In animals, including nonhuman primates, MDMA is known to damage brain serotonin (5-hydroxytryptamine; 5-HT) neurons. It is not known whether MDMA damages serotonin neurons in the human brain but there is some indication that it may. Although the large...